$0.725
+0.020 (+2.82%)收盤時
ESLA 資訊
ESLA 事件
Estrella Immunopharma Activates Fourth Clinical Site for STARLIGHT-1 Trial
Estrella Immunopharma announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, NHL. The new site, University Hospitals Cleveland Medical Center, an affiliated teaching hospital of Case Western Reserve University School of Medicine, is expected to begin screening and enrolling patients following completion of site initiation activities.
Estrella Immunopharma Activates Second Clinical Site for STARLIGHT-1 Trial
Estrella Immunopharma announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, NHL. The new site, Baylor Research Institute d/b/a Baylor Scott & White Research Institute in Dallas, Texas, has begun screening and enrolling patients.
Estrella Immunopharma Successfully Doses First Patient with EB103
Estrella Immunopharma announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma, NHL. "This marks an important milestone for Estrella and STARLIGHT-1," said Cheng Liu, PhD, Chief Executive Officer of Estrella. "The sustained complete responses observed to date reinforce EB103's potential to deliver best-in-class outcomes for patients with R/R B-cell NHL. We remain deeply committed to advancing EB103."
Estrella Immunopharma STARLIGHT-1 Trial Shows 100% Complete Response Rate
Estrella Immunopharma presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT & CIBMTR Tandem Meetings. The oral presentation highlighted clinical data from the Company's ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma. In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated a 100% Complete Response rate in the high-dose cohort at Month 1. Notably, all patients who achieved a CR have remained in CR through the data cutoff. The median Duration of Complete Response has not yet been reached, with response durations currently ranging from 3 to 18 months. Clinical highlights also include a complete responder with Primary Central Nervous System Lymphoma, a highly aggressive NHL subtype with an extremely poor prognosis of about 30% 5-year survival rate.
Estrella Immunopharma Advances STARLIGHT-1 Trial to Phase II
Estrella Immunopharma announced that an independent Data Safety Monitoring Board has completed its review of safety data from the Phase I dose escalation portion of the STARLIGHT-1 trial. Based on the safety profile observed, the DSMB recommended advancing the trial to Phase II, or the expansion phase, at the Recommended Phase II Dose. The expansion phase will further evaluate the safety and preliminary efficacy of EB103, the company's CD19-redirected Artemis T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma. In the Phase I dose escalation phase, no treatment-related serious adverse events were reported. The high-dose cohort achieved a 100% complete response rate at Month 1 in all evaluable patients.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。